Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer

Executive Summary

ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.


Related Content

ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV
Start-Up Quarterly Statistics, Q2 2016
ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy